{ "items": [ "\n\n
\n \n 21 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nAn international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues in the Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine) report the unequal impacts of public health measures, and the prevalence of \u2018fake news\u2019.
\n \n\n\n \n 19 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThree projects at Oxford have received funding from NIHR to assess breathlessness in Long COVID patients, investigate the impact of Long COVID on families, and examine the role of vaccines in Long COVID.
\n \n\n\n \n 19 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nCOVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.
\n \n\n\n \n 19 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nAdenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.
\n \n\n\n \n 15 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nA new study by researchers at the University of Oxford, Queen Mary University of London, Institute for Advanced Studies, Vienna, and the Medical University of Graz, has found that lateral flow tests detect Covid-19 with similar accuracy to laboratory-based PCR tests, providing they are used at the onset of infection and soon after symptoms start.
\n \n\n\n \n 14 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 7 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 30 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nUsing the full pseudonymised GP records of 57.9 million patients in England, researchers at Oxford University and the London School of Hygiene and Tropical Medicine have found that formally recorded diagnoses of Long COVID are substantially lower than previous survey estimates for the same condition.
\n \n\n\n \n 30 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nAlternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nResearch on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine \u2018AZD2816\u2019 in volunteers against the B.1.351 variant of concern \u2013 commonly known as the Beta variant.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers from the University of Oxford have today released their findings about the so-called \u2018correlates of protection\u2019 against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
\n \n\n\n \n 23 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nFrom today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world\u2019s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
\n \n\n\n \n 21 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nA new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
\n \n\n\n \n 17 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.
\n \n\n\n \n 16 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nA new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.
\n \n\n\n \n 16 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.
\n \n\n\n \n 14 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe largest, most extensive global network study on background rates for adverse events of special interest identifies important age, sex and database differences that should inform future safety surveillance efforts.
\n \n\n\n \n 10 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nScientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.
\n \n\n\n \n 9 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nCreated in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.
\n \n\n